Literature DB >> 7609067

Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.

M J Bouchard1, D H Lam, V R Racaniello.   

Abstract

To identify determinants of attenuation in the poliovirus type 1 Sabin vaccine strain, a series of recombinant viruses were constructed by using infectious cDNA clones of the virulent type 1 poliovirus P1/Mahoney and the attenuated type 1 vaccine strain P1/Sabin. Intracerebral inoculation of these viruses into transgenic mice which express the human receptor for poliovirus identified regions of the genome that conferred reduced neurovirulence. Exchange of smaller restriction fragments and site-directed mutagenesis were used to identify the nucleotide changes responsible for attenuation. P1/Sabin mutations at nucleotides 935 of VP4, 2438 of VP3, and 2795 and 2879 of VP1 were all shown to be determinants of attenuation. The recombinant viruses and site-directed mutants were also used to identify the nucleotide changes which are involved in the temperature sensitivity of P1/Sabin. Determinants of this phenotype in HeLa cells were mapped to changes at nucleotides 935 of VP4, 2438 of VP3, and 2741 of VP1. The 3Dpol gene of P1/Sabin, which contains three amino acid differences from its parent P1/Mahoney, also contributes to the temperature sensitivity of P1/Sabin; however, mutants containing individual amino acid changes grew as well as P1/Mahoney at elevated temperatures, suggesting that either some combination or all three changes are required for temperature sensitivity. In addition, the 3'-noncoding region of P1/Sabin augments the temperature-sensitive phenotype conferred by 3Dpol. Although nucleotide 2741, 3Dpol, and the 3'-noncoding region of P1/Sabin contribute to the temperature sensitivity of P1/Sabin, they do not contribute to attenuation in transgenic mice expressing the poliovirus receptor, demonstrating that determinants of attenuation and temperature sensitivity can be genetically separated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609067      PMCID: PMC189313          DOI: 10.1128/JVI.69.8.4972-4978.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

2.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

3.  Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.

Authors:  A J Cann; G Stanway; P J Hughes; P D Minor; D M Evans; G C Schild; J W Almond
Journal:  Nucleic Acids Res       Date:  1984-10-25       Impact factor: 16.971

4.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

5.  Analysis of RNA synthesis of type 1 poliovirus by using an in vitro molecular genetic approach.

Authors:  H Toyoda; C F Yang; N Takeda; A Nomoto; E Wimmer
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

6.  Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984.

Authors:  B M Nkowane; S G Wassilak; W A Orenstein; K J Bart; L B Schonberger; A R Hinman; O M Kew
Journal:  JAMA       Date:  1987-03-13       Impact factor: 56.272

7.  Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.

Authors:  N La Monica; C Meriam; V R Racaniello
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

8.  Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition.

Authors:  E M Colston; V R Racaniello
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.

Authors:  A Nomoto; T Omata; H Toyoda; S Kuge; H Horie; Y Kataoka; Y Genba; Y Nakano; N Imura
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

10.  Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies.

Authors:  N La Monica; W J Kupsky; V R Racaniello
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

View more
  54 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture.

Authors:  K Matsuura; M Ishikura; H Yoshida; T Nakayama; S Hasegawa; S Ando; H Horie; T Miyamura; T Kitamura
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

3.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

5.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

9.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene.

Authors:  Kok Keng Tee; Tommy Tsan-Yuk Lam; Yoke Fun Chan; Jon M Bible; Adeeba Kamarulzaman; C Y William Tong; Yutaka Takebe; Oliver G Pybus
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.